AstraZeneca’s oncology immunotherapy Imfinzi (durvalumab) met the second primary endpoint of overall survival in the phase III trial for unresectable stage III non-small cell lung cancer (NSCLC).
Midatech has commenced initial dosing in the first in-human study of its sustained release product Q-Octreotide (MTD201) for the treatment of carcinoid cancer and acromegaly.
Janssen Pharmaceutical's androgen receptor inhibitor Erleada (apalutamide) succeeded in a phase 3 trial by significantly cutting down the risk of prostate specific antigen (PSA) progression in patients having non-metastatic castration-resistant prostate cancer (nmCRPC).
Pfizer has reported positive top-line results from a phase 3 study, which assessed the use of Lyrica (pregabalin) oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.
Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.
Merck has agreed to invest $125m in Moderna Therapeutics under a new agreement that expands the firms’ 2016 partnership to develop messenger RNA (mRNA) cancer vaccines.
Karyopharm Therapeutics’ selinexor, an oral selective inhibitor of nuclear export (SINE) compound, has succeeded in a phase 2b study by showing a 25.4% overall response rate (ORR) in heavily pretreated patients with refractory multiple myeloma.
Allergan’s migraine drug ubrogepant has succeeded in a phase 3 trial by meeting its co-primary endpoints for a 50mg dose.
Vertex Pharmaceuticals has initiated two phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF).
Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.